Wundert mich ja auch. Ich wollte verkaufen, aber bei Tradegate wurde kein Kurs gestellt. Dann habe ich auf anderen Handelsplätzen geschaut, dort auch nicht. Gerade könnte ich max. 342 Stück für 3,50 EURO verkaufen. Mehr geht nicht. Ist doch ein Witz. Wollte schon mehrmals, wenn ich im plus war, Teilverkäufe machen. War mir aber nicht möglich.
Dann stell doch trotzdem deine gewünschte Stückzahl rein. Vielleicht ein paar Cent tiefer. Irgendwann werden die schon weggehen. (Teilausführungen werden ja m.M.n. nicht mehr doppelt mit Gebühren belegt)
Nicht mal das hilft... - "Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy
SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate, also known as a capsid inhibitor, vebicorvir (VBR), in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for the treatment of patients with chronic HBV infection. The companies announced a clinical collaboration agreement in August 2020.
The randomized, multi-center, open-label Phase 2 clinical trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triple combination of VBR, AB-729 and an NrtI compared to the double combinations of VBR with an NrtI and AB-729 with an NrtI. Approximately 60 virologically-suppressed patients with HBeAg negative chronic HBV are expected to be enrolled across these three treatment arms. Patients will be dosed for 48 weeks with VBR 300 mg orally once daily and AB-729 60 mg subcutaneously every 8 weeks, with a 48-week follow-up period. The primary objective of the trial is to evaluate the safety and tolerability of the triple combination, while secondary objectives of the trial include evaluating the effect of the triple combination in reducing HBV viral biomarkers such as HBV DNA, HBV pgRNA and HBsAg. Additional cohorts may be added in the future to evaluate other patient populations and/or combinations... https://investor.arbutusbio.com/news-releases/...rma-initiate-phase-2
"Arbutus owns approximately 16% of the common equity of Genevant Sciences Ltd. (“Genevant”), a company Arbutus launched with Roivant Sciences, Ltd. and to which Arbutus licensed exclusive rights to its lipid nanoparticle ("LNP") and ligand conjugate delivery technologies for RNA-based applications outside of HBV. We are entitled to receive tiered low single-digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sub-licenses the intellectual property licensed by us to Genevant, we are entitled to receive, upon the commercialization of a product developed by such sub-licensee, the lesser of (i) twenty percent of the revenue received by Genevant for such sublicensing and (ii) tiered low single-digit royalties on product sales by the sublicensee.." https://investor.arbutusbio.com/news-releases/...r-end-2020-financial
und "...back to the patent case that was announced last year where there was a challenge against one of Arbutus patents and was found in our favor. And I think as we described at the time and subsequently in our various listings, that patent is one of those that has been licensed out to Genevant, which Dave described in his comments this morning. So, unfortunately, it's really not possible for us at Arbutus to comment on what Genevant may or may not be doing. Suffice to say that as part of that license-out arrangement, we've got some very clear terms for any sublicensing that Genevant may do, which is what Dave summarized in his comments. So I think that's about all that we can say..."
Ich kapiere diese Zurückhaltung auch nicht wirklich.. Man schiebt das auf die Vertragsausgestaltung mit Genevant.. ("unfortunately, it's really not possible for us at Arbutus to comment on what Genevant may or may not be doing.") Anstatt mal Feuer frei zu rufen und tacheles zu reden..
Der Aktienkurs verheißt leider nichts Gutes. Entweder, weil die Leute keinen Erfolg im Patentstreit sehen oder das Ding längst entschieden ist. Keine Ahnung..
Aus meiner Sicht ist das noch offen und weiterhin spannend. Ich gehe weiterhin davon aus, dass sich die 16%-Beteiligung und die (in #611) genannten Anteile an Produkten auszahlen sollten.
so ist das leider manchmal. Und die beiden Jungs, die hier am aktivsten waren sind weg. Planetpaprika hat sich Ende Januar offiziell in den Ruhestand verabschiedet und experavits Konto ist gelöscht. Man muss aber für seine Entscheidungen eh selber geradestehen und nicht auf Trommler hören.
Ja , Anfang des Jahres hat Planetpaprika folgendes geschrieben:
"Ganz ehrlich, das ist die einzige Aktie in meinem Depot, die ich blind nachkaufe und sammel, Chart hin oder her, buying all dips & long. Zum Kurs kann ich nur sagen, daß es immer-noch.... immer-wieder Einstiegskurse sind."
Wahrscheinlich hat er bei den extremen Ausbrüchen soviel Geld gescheffelt, dass er das oben gechriebene nicht mehr braucht.
Seite 14/15 COVID-19 Research Efforts "While our core mission is to find a cure for HBV, the magnitude of the coronavirus pandemic is undeniable. Given our proven expertise in the discovery of new antiviral therapies, we initiated a drug discovery effort for treating coronaviruses, including COVID-19, in 2020. To that end, we have assembled an internal team of expert scientists under the direction of our Chief Scientific Officer, Dr. Michael Sofia, to identify novel small molecule therapies to treat COVID-19 and future coronavirus outbreaks. Dr. Sofia, who was awarded the Lasker-DeBakey Award for his discovery of sofosbuvir, brings extensive antiviral drug discovery experience to this new program. We are also a member of the COVID R&D consortium to address the SARS-CoV-2 pandemic and any future coronavirus outbreaks. At this time, our COVID-19 research program is focused on the discovery and development of new molecular entities that address specific viral targets including the nsp12 viral polymerase and the nsp5 viral protease. These targets are essential viral proteins which we have experience in targeting. We are actively screening multiple new oral molecular entities."
Seite 17/18 "We have a portfolio of approximately 55 patent families, in the United States and abroad, that are directed to our therapeutic HBV product candidates, HBV technology and various aspect of LNPs and LNP formulations. The portfolio includes approximately 150 issued patents throughout the world and an extensive portfolio of pending patent applications. The earliest any of the material patents with respect to our current product candidates will expire is 2037."
Seite 27/28 "..In February 2021, Arbutus Biopharma US Holdings, Inc. merged with Arbutus Biopharma, Inc. with Arbutus Biopharma, Inc. as the surviving entity."
Seite 100/101 Series A Participating Convertible Preferred Shares "In October 2017, we entered into a subscription agreement with Roivant Sciences Ltd., or Roivant, for the sale of 1,164,000 Series A participating convertible preferred shares, or the Preferred Shares, for gross proceeds of $116.4 million. These Preferred Shares are non-voting and accrue an 8.75% per annum coupon in the form of additional Preferred Shares, compounded annually, until October 18, 2021, at which time all the Preferred Shares will be subject to mandatory conversion into common shares (subject to limited exceptions in the event of certain fundamental corporate transactions relating to our capital structure or assets, which would permit earlier conversion at Roivant’s option).
The conversion price is $7.13 per share, which will result in the Preferred Shares being converted into approximately 23 million common shares. After conversion of the Preferred Shares into common shares, based on the number of common shares outstanding as of March 3, 2021, Roivant would hold approximately 33% of our common shares. Roivant agreed to a four year lock-up period for this investment and its existing holdings in us. Roivant also agreed to a four year standstill whereby Roivant will not acquire greater than 49.99% of our common shares or securities convertible into common shares. The initial investment of $50.0 million closed in October 2017, and the remaining amount of $66.4 million closed in January 2018 following regulatory and shareholder approvals." - (Genauer gesagt enden die 4 Jahre am 18.10.2021)
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection https://investor.arbutusbio.com/news-releases/...-initiate-phase-1a1b Mar 16, 2021 WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has received regulatory approval to initiate a Phase 1a/1b clinical trial with AB-836, its proprietary oral capsid inhibitor for the treatment of HBV infection.
“We are pleased that we have received regulatory approval to proceed with our Phase 1a/1b clinical trial for AB-836, and we expect to begin dosing shortly. Initiation of this trial is an important step towards potential future proprietary combinations with AB-729 and other mechanisms,” said William Collier, President and Chief Executive Officer of Arbutus.
Dr. Michael Sofia, Chief Scientific Officer of Arbutus, added, “Based on pre-clinical studies with AB-836, which is derived from a novel chemical series in this class, we believe it has the potential for improved clinical efficacy and safety as well as a favorable resistance profile relative to earlier generation capsid inhibitors. In addition, we believe that the strong potency of AB-836 as shown in in vitro testing should allow active engagement of the second mechanism of inhibiting cccDNA replenishment at clinically relevant doses.” ...
Woher kommen eigentlich diese extremen Schwankungen, diese Volatilität? Das sind ja bis zu 25 % Unterschied im Wert. Plötzlich steigt der Wert um fast 10 %, um anchließend wieder in ein tiefes Loch zu fallen.
Auch das wird vermutlich durch die geringen Umsätze verursacht. Auch durch große Spreads bei bid/ask. Es geht den meisten wohl wie uns.. Man weiß nicht so recht wie es weitergeht und hofft auf eine Patent- Entscheidung zu Gunsten ABUS oder wenigstens Einnahmen via Genevant-Anteil. Wenn allerdings Genevant und Arbutus den gleichen Großaktionär haben (Roivant) dann ist halt schwer zu sagen, was da für Arbutus hängen bleibt..